US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved a new Opdivo (nivolumab) ...

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) ...

BioNTech (NASDAQ:BNTX) surged 20% after Bristol Myers Squibb agreed to license its bispecific antibody BNT327targeting PD-L1 ...

The CheckMate 901 trial compared Opdivo-Yervoy with gemcitabine-carboplatin for cisplatin-ineligible metastatic urothelial carcinoma patients. Despite negative trial results, the FDA approved Opdivo ...

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...